



07-05-02

RECEIVED
AUG 1 2002

GP # 1615

TECH CENTER 1600/2000
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**FEE TRANSMITTAL**
for FY 2002

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$)

Complete if Known 09/835,501

Application Number

Filing Date

First Named Inventor

Examiner Name

Group Art Unit

Attorney Docket No.

Tyler Parr, Ph.D.

Robert M Joyner

1615

JUL 11 2002

RECEIVED

METHOD OF PAYMENT (check all that apply)☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☐ Deposit Account:Deposit Account Number
Deposit Account Name

The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Credit any overpayments☐ Charge any additional fee(s) during the pendency of this application☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
101 740	201 370	Utility filing fee	
106 330	206 165	Design filing fee	
107 510	207 255	Plant filing fee	
108 740	208 370	Reissue filing fee	
114 160	214 80	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	X	
Multiple Dependent	-3** =	X	

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description
103 18	203 9	Claims in excess of 20
102 84	202 42	Independent claims in excess of 3
104 280	204 140	Multiple dependent claim, if not paid
109 84	209 42	** Reissue independent claims over original patent
110 18	210 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
105 130	205 65	Surcharge - late filing fee or oath	
127 50	227 25	Surcharge - late provisional filing fee or cover sheet	
139 130	139 130	Non-English specification	
147 2,520	147 2,520	For filing a request for ex parte reexamination	
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	
115 110	215 55	Extension for reply within first month	
116 400	216 200	Extension for reply within second month	
117 920	217 460	Extension for reply within third month	
118 1,440	218 720	Extension for reply within fourth month	
128 1,960	228 980	Extension for reply within fifth month	
119 320	219 160	Notice of Appeal	
120 320	220 160	Filing a brief in support of an appeal	
121 280	221 140	Request for oral hearing	
138 1,510	138 1,510	Petition to institute a public use proceeding	
140 110	240 55	Petition to revive - unavoidable	
141 1,280	241 640	Petition to revive - unintentional	
142 1,280	242 640	Utility issue fee (or reissue)	
143 460	243 230	Design issue fee	
144 620	244 310	Plant issue fee	
122 130	122 130	Petitions to the Commissioner	
123 50	123 50	Processing fee under 37 CFR 1.17(q)	
126 180	126 180	Submission of Information Disclosure Stmt	\$180
581 40	581 40	Recording each patent assignment per property (times number of properties)	
146 740	246 370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149 740	249 370	For each additional invention to be examined (37 CFR § 1.129(b))	
179 740	279 370	Request for Continued Examination (RCE)	
169 900	169 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Name (Print/Type)	Tyler Parr, Ph.D.	Registration No. (Attorney/Agent)	Telephone	(323) 865-0506
Signature	Tyler Parr	Date	29 Jun 02	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


07/10/2002 RUSMANI 00000070 09853501

01 FC:126

180.00 DP

RECEIVED

AUG 21 2002



TECH CENTER 1600/2900

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4**Complete if Known**

Application Number 09/053,501
 Filing Date 04/16/2001
 First Named Inventor Tyler Parr
 Art Unit 1615
 Examiner Name Robert M. Joyner
 Attorney Docket Number

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		US- 5855920		01-05-1999	Chein	Pg 1
		US- 4411890		10-25-1983	Momany	Pg 1
		US- 5576351		11-19-1996	Yoshimura et al.	Pg 1
		US- 6166077		12-26-2000	De Simone	Pg 5
		US- 5240961		08-31-1993	Shug	Pg 3
		US- 5817329		10-06-1998	Gardiner	Pg 1
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

RECEIVED

JUL 16 2002

JUL 16 2002 MAIL ROOM

FOREIGN PATENT DOCUMENTS


Examiner Initials	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ - Kind Code ⁵ (if known)				
			WO 9959543-A	11-25-1999	Ma	Pg 1	
			WO 97/06803	02-27-1997	Dodge	Pg 7	
			WO 9640105-A	12-19-1996	van Cauter	Pg 1	
			WO 9744042-A	11-27-1997	van Cauter	Pg 5	
			WO 0021526-A	10-09-1998	Cavazza	Pg 1	
			WO 0011968-A	08-19-1999	Cavazza	Pg 1	
			WO 0028986-A	05-25-2000	Cavazza	Pg 1	
			WO 9801128	01-15-1998	Mendes	Pg 1	
			WO 98/44793	10-15-1998	Grant	Pg 1	
			WO 00/64283	04-27-2000	White	Pg 1	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	09/853,501
Filing Date	04/16/2001
First Named Inventor	Tyler Parr, PhD
Group Art Unit	1615
Examiner Name	Robert M. Joyner
Attorney Docket Number	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		1. Kojima M., Hosoda H., Date Y., Makazato M., Matsuo H., Kangawa K. (1999) Ghrelin is a growth-hormone-releasing acylated peptide ... Nature 402:656-660	
		2. van Coevorden A., Mockel J., Laurent E., Kerkhofs M., L'Hermite-Baleriaux M., Decoster C., Neve P., van Cauter E. (1991) Neuroendocrine rhythms and sleep in aging men. Am J Physiol 260:E651-E661	
		3. Mendelson W.B., Lantigua R.A., Wyatt R.J., Gillin C., Jacobs L.S. (1981) Piperidine Enhances Sleep-Related and Insulin-Induced Growth Hormone Secretion. J. Clin. Endocrinol. Metab. 52:409-415	
		4. van Cauter E, FW Turek 1995 Endocrine and Other Biological Rhythms. In: DeGroot LJ (eds) Endocrinology 3rd Ed. Vol 3. W. B. Saunders Co., Philadelphia, pp 2487-2548	
		5. Muller EE 1995 Role of Neurotransmitters and Neuromodulators in the Control of Anterior Pituitary Hormone Secretion. In: DeGroot LJ (eds) Endocrinology, 3rd Edition, Vol. 1, pp 178-191	
		6. Wass JA, M Besser 1995 Tests of Pituitary Function. In: DeGroot LJ (eds) Endocrinology 3rd Ed. Vol. 1. W.B. Saunders Co., Philadelphia, pp 487-496	
		7. Parker M.L., hammond J.M., Daughaday W.H. (1967) The Arginine Provocative Test: An Aid in the Diagnosis of Hyposomatotropism. J Clin Endocrinol. Metab. 27:1129-1136	
		8. Corpas E., Blackman M.R., Robertson R., Scholfield D., Harman S.M. (1993) Oral Arginine-Lysine Does not Increase Growth Hormone or Insulin-like Growth Factor-I in Old Men. J. Gerontol. 48:M128-M133	
		9. Chin M.-Y., Kreutzer R.A. (1992) Acute Poisoning from g-Hydroxybutyrate in California. W J Med 156:380-384	
		10. Parr T. (1996) Insulin Exposure Controls the Rate of Mammalian Aging. Mech Ageing Dev 88:75-82	
		11. Parr T. (1997) Insulin Exposure and Aging Theory. Gerontology 43:182-200	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

AUG 21 2002

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Espionage Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TECH CENTER 1600/2900

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/853,501
		Filing Date	04/16/2001
		First Named Inventor	Tyler Parr
		Group Art Unit	1615
		Examiner Name	Robert M. Joyner
Attorney Docket Number			
Sheet	3	of	4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the book (when appropriate), issue, volume, page number(s), publisher, city and/or country where published	T ²
		12. Parr T.B. (1999) Insulin Exposure and Unifying Aging Gerontology 45:121-135	
		13. Parr T.B. (2001) A New Technique to Elevate of Night Time Growth Hormone Release and a Potential Growth Hormone Feedback Control Loop. Med Hypotheses 56:610-613	
		14. Paradies G., Ruggiero F.M., Petrosillo G., Gadaleta M.N., Quagliariello E. (1994) The Effect of Aging and Acetyl-L-carnitine on the Function and on the Lipid Composition.... Ann. N. Y. Acad. Sci. 717: 233-243	
		15. Buttgerit F., Brand M.D. (1995) A hierarchy of ATP-consuming processes in mammalian cells..Biochem J.312:163-167	
		16. Castorina M., Ferraris L. (1994) Acetyl-L-carnitine affects aged brain receptor system in rodents. Life Sci 54:1205-1214	
		17. Ranke MB 1995 Growth Hormone Insufficiency: Clinical Features, Diagnosis, and Therapy. In: DeGroot LJ (eds) Endocrinology 3 rd Ed.. W. B. Saunders Co., Philadelphia, pp	
		18. Besset A., Bonardet A., Roundouin G., Descommps B., Passouant P. (1982) Increase in sleep related GH and Prl secretion after chronic agrinine aspartate administration in man. Acta Endocrinol 99:18-23	
		19. Spagnoli A., Lucca U., Menasce G., Bandera L., Cizza G., Forloni G., Tettamanti M., Frattura L., Tiraboschi P., Comelli M., Senin U., Longo A., Petrini A., Brambilla G., Belloni A., Negri C., Cavazzuti F., Salsi A., Calogero P., Parma E., Stramba-Bidiale M., Vitali S., Andreoni G., Inzoli M.R., Santus G., Caregnato R., Peruzza M., Favaretto M., Bozeglav C., Alberoni M., Ed Leo D., Serraiotto L., Baiocchi A., Sciccia S., Culotta P., Ieracitano D. (1991) Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 41:1726-1732	
		20. Bowman B.A. (1992) Acetyl-carnitine and Alzheimer's disease. Nutr Rev 50:142-144	
		21. Pettegrew J.W., Klunk W.E., Panchalingam K., Kanfer J.N., McClure R.J. (1995) Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging 16:1-4	
		22. Goa K.L., Brogden R.N. (1987) L-Carnitine A Preliminary Review of its Pharmacokinetics, and its Therapeutic use in Ischemic Cardiac Diseases and Primary and Secondary Carnitine Deficiencies.... Drugs 34:1-24	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

JUL 11 2002

RECEIVED

RECEIVED

JUL 16 2002
MAIL ROOM

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.